¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"specific reaction rate"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
group-specific
±ºÆ¯ÀÌ-
group-specific antigen
¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
neuron-specific enolase
´º·±Æ¯ÀÌ¿¡³î¶ó¾ÆÁ¦
organ specific antigen
Àå±âƯÀÌÇ׿ø
platelet-specific antigen
Ç÷¼ÒÆÇƯÀÌÇ׿ø
prostate specific antigen
Àü¸³»ùƯÀÌÇ׿ø
species-specific
Á¾Æ¯ÀÌ-
species-specific antigen
Á¾Æ¯ÀÌÇ׿ø
species-specific reactivity
Á¾Æ¯À̹ÝÀÀ¼º
specific
1. ƯÀÌ-, ƯÁ¤- 2. Á¾-
specific action
ƯÀÌÀÛ¿ë
specific activity
1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
specific antagonist
ƯÀÌ´ëÇ×Á¦
specific antigen
ƯÀÌÇ׿ø
specific charge
ºñÀüÇÏ, °ßÁÜÀüÇÏ
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
chain reaction
¿¬¼â¹ÝÀÀ
complement fixation reaction
µµ¿òü°áÇÕ¹ÝÀÀ, º¸Ã¼°áÇÕ¹ÝÀÀ
cross reaction
±³Â÷¹ÝÀÀ
delayed reaction
Áö¿¬¹ÝÀÀ
graft versus host reaction
ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
inhibition reaction
¾ïÁ¦¹ÝÀÀ
initial reaction
Ãʱâ¹ÝÀÀ
late reaction
(¢¡delayed reaction) Áö¿¬¹ÝÀÀ
periosteal reaction
»À¸·¹ÝÀÀ, °ñ¸·¹ÝÀÀ
phobic reaction
°øÆ÷¹ÝÀÀ
polymerase chain reaction
ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ, ÁßÇÕ¿¬¼â¹ÝÀÀ
pyrogenic reaction
¹ß¿¹ÝÀÀ
rejection reaction
°ÅºÎ¹ÝÀÀ
reversible reaction
°¡¿ª¹ÝÀÀ
second order reaction
ÀÌÂ÷¹ÝÀÀ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
organ specific antigen
Àå±âƯÀÌÇ׿ø
platelet-specific antigen
Ç÷¼ÒÆÇƯÀÌÇ׿ø
specific action
ƯÀÌÀÛ¿ë
specific activity
ºñ¹æ»ç´É, ƯÀÌȰ¼ºµµ
specific antagonist
ƯÀÌ´ëÇ×Á¦
specific antigen
ƯÀÌÇ׿ø
specific pathogen free animal
ƯÁ¤¹«º´¿øÃ¼µ¿¹°
type specific antigen
ÇüƯÀÌÇ׿ø
blood group specific substance
Ç÷¾×ÇüƯÀ̹°Áú
specific charge
°ßÁÜÀüÇÏ, ºñÀüÇÏ
specific compliance
ƯÀÌź¼º, ƯÀÌÀ¯¼øµµ, ƯÀÌÀÀ¶ô
specific conductivity
ºñÀüµµÀ²
specific electric conductivity
ºñÀü±âÀüµµÀ²
donor-specific phage
Á¦°øÃ¼Æ¯ÀÌÆÄÁö, ÁÖ°ÔÆ¯ÀÌÆÄÁö
specific disease
ƯÀÌÁúȯ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
platelet-specific antigens
Ç÷¼ÒÆÇƯÀÌÇ׿ø
pneumococcal [specific] polysaccharide
Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
polysaccharide, pneumococcal [specific]
Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
prostate specific antigen
Àü¸³¼±Æ¯ÀÌÇ׿ø
prostate-specific antigen
Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
prostatic specific antigen
Àü¸³¼± ƯÀÌÇ׿ø
BMR=£¾basal metabolic rate
±âÃÊ´ë»çÀ²
GFR => glomerular filtration rate
»ç±¸Ã¼¿©°úÀ²
GFR= glomerular filtration rate
»ç±¸Ã¼(ÞêϹô÷)°Å¸§·ü(×È).
GFR= glomerular filtration rate
»ç±¸Ã¼°Å¸§·ü.
Heart rate
½É¹Ú¼ö(ãýÚÑâ¦)
MVR=£¾maximus voiding rate
ÃÖ´ë¹è´¢À².
Westergren sedimentation rate
¿þ½ºÅͱ׷»Ä§°¼Óµµ
absorbed dose rate
Èí¼ö¼±·®À²
actual death rate
½ÇÁ¦»ç¸Á·ü(ËàÌ¡Ë×ËÎËô).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
untoward effect =adverse reaction, unwanted reaction
À¯ÇعÝÀÀ(êóúªÚãëë), ºÎÀÛ¿ë
untoward effect =adverse reaction, unwanted reaction
À¯ÇعÝÀÀ(êóúªÚãëë), ¾àÇØ(å·úª)¹ÝÀÀ.[¾à¸®]ºÎÀÛ¿ë, ºÒ¿øÀÛ¿ë.
upgrading reaction => reversal reaction
¿ªÇà¹ÝÀÀ
antigen, species-specific
Á¾Æ¯ÀÌÇ׿ø
antigen, tumor-specific
Á¾¾çƯÀÌÇ׿ø
antigen, tumor-specific transplantation
Á¾¾çƯÀÌ À̽ÄÇ׿ø
antigen,tumor-specific transplantation
Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
blood group specific substance
Ç÷¾×ÇüƯÀ̹°Áú.
bulk specific gravity
¿ëÀûºñÁß(é»îÝÝïñì)
donor-specific phage
°ø¿©±ÕƯÀÌÆÄÁö
granulocyte-specific antigens
°ú¸³±¸Æ¯ÀÌÇ׿ø
group specific C carbohydrate
±ºÆ¯ÀÌ C´Ù´çü.
group-specific
±ºÆ¯ÀÌÀÇ
group-specific C carbohydrate
±ºÆ¯ÀÌ C ź¼öȹ°
group-specific antigen
±º-ƯÀÌÇ׿ø
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½